Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 31.20
+0.54 (1.76%)
Oct 31, 2025, 12:59 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 30.80M SEK in the quarter ending September 30, 2025, a decrease of -36.70%. This brings the company's revenue in the last twelve months to 178.61M, down -5.69% year-over-year. In the year 2024, Hansa Biopharma AB had annual revenue of 171.32M with 27.76% growth.
Revenue (ttm)
178.61M
Revenue Growth
-5.69%
P/S Ratio
17.78
Revenue / Employee
1.28M
Employees
135
Market Cap
3.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
| Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
| Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
| Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
| Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.22B |
| Elekta AB | 17.84B |
| Asker Healthcare Group AB | 15.88B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vitrolife AB | 3.51B |
Hansa Biopharma AB News
- 2 days ago - Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results - PRNewsWire
- 4 days ago - Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results - PRNewsWire
- 5 weeks ago - Hansa Biopharma AB (publ) Discusses on ConfIdeS US Phase 3 Pivotal Trial Topline Results Presentation - Seeking Alpha
- 5 weeks ago - Hansa Biopharma AB (publ) - Special Call - Seeking Alpha
- 5 weeks ago - Hansa Biopharma AB (Publ) Discusses On ConfIdeS US Phase 3 Pivotal Trial Topline Results Call (Transcript) - Seeking Alpha
- 3 months ago - Hansa Biopharma announces key executive appointments to support continued growth - PRNewsWire
- 3 months ago - Hansa Biopharma AB (publ) 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha